glp-1 obesity drug news Only one in 12 remain on a for at three years The GLP-1 Access Gap: Mapping

If patients have a severe obesity-related complication including but not limited to hypertension, type 2 diabetes, CVD, dyslipidemia and a BMI of 27 mg/kg 2 or greater, then concurrent initiation of weight-loss medication with lifestyle interventions can be considered, according to the guideline

& Loukas, Y

PubMed ID: 11673763 Mor MI et al

However, at 1,000 mg/kg, it slowed embryo development, as indicated by reduced crown-rump length, somite count, and lower morphological scores

Realistic Expectations and the Phased Journey In a world of "instant results" and "overnight transformations," we prefer to speak the truth: real change takes time